Skip to main content
SpringerLink
Log in
Book cover

Molecular Cytogenetics pp 311–342Cite as

Interphase FISH Studies of Chronic Myeloid Leukemia

  • Protocol

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 204))

Abstract

This chapter deals with the application of fluorescence in situ hybridization (FISH) to study interphase nuclei from patients with chronic myeloid leukemia (CML). In our experience, FISH for BCR/ABL fusion detects all forms of the Philadelphia (Ph) chromosome (1,2). FISH is a valuable adjunct to conventional cytogenetic studies and can be applied to the same preparations. Because FISH is useful for quantifying proliferating neoplastic cells in metaphase and non-proliferating cells in interphase, it is particularly useful in assessing response to therapy using either peripheral blood or bone marrow (2,3). This chapter discusses ways to gain experience and validate all aspects of FISH-based testing with BCR and ABL probes. In addition, methods for assuring quality are discussed for FISH-based testing with the BCR and ABL probes used in routine clinical practice.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Dewald G. W., Schad C. R., Christensen E. R., et al. (1993) The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet. Cytogenet. 71, 7–14.

    Article  CAS  PubMed  Google Scholar 

  2. Dewald G. W., Wyatt W. A., Juneau A. L., et al. (1998) Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 91, 3357–3365.

    CAS  PubMed  Google Scholar 

  3. Bu~no I., Wyatt W. A., Zinsmeister A. R., Dietz-Band J., Silver R. T., and Dewald G. W. (1998) A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 92, 2315–2321.

    CAS  Google Scholar 

  4. Schad C. and Dewald G. (1995) Building a new clinical test for fluorescence in situ hybridization. App. Cytogenet. 21, 1–4.

    Google Scholar 

  5. ACMG (ed.) (1999) American College of Medical Genetics Laboratory Practice Committee Standards and Guidelines for Clinical Genetics Laboratories. American College of Medical Genetics Bethesda, MD.

    Google Scholar 

  6. CAP (ed.) (2000) College of American Pathologists Cytogenetics Inspection Checklists. College of American Pathologists, Northfield, IL.

    Google Scholar 

  7. NYDH (ed.) (2000) New York Dept. of Health, Wadsworth Center for Laboratories and Research Genetics Laboratory Checklists. New York State Department of Health, New York.

    Google Scholar 

  8. First International Workshop on Chromosomes in Leukaemia. (1978) Chromosomes in Ph1-positive chronic granulocytic leukaemia. Br. J. Haematol. 39, 305–309.

    Article  Google Scholar 

  9. Demetrick D. J., Dewald G. W., Lanman J., and Bahou W. F. (1996) The thrombin receptor gene is centromeric to the common proximal breakpoint in patients with the 5q-syndrome: identification of a previously unrecognized chromosome 5 inversion. Br. J. Haematol. 92, 339–343.

    Article  CAS  PubMed  Google Scholar 

  10. Matsue K., Miyamoto T., Ito M., and Tsukuda K. (1995) Late appearance of the Philadelphia chromosome with monosomy 7 in a patient with de novo AML with trilineage myelodysplasia. Am. J. Hematol. 49, 341–346.

    Article  CAS  PubMed  Google Scholar 

  11. Bloomfield C. D., Goldman A. I., Alimena G., et al. (1986) Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67, 415–420.

    CAS  PubMed  Google Scholar 

  12. Ribeiro R., Abromowitch M., Raimondi S., Murphy S., Behm F., and Williams D. (1987) Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70, 948–953.

    CAS  PubMed  Google Scholar 

  13. Mitelman F. (ed.) (1995) An International System for Human Cytogenetic Nomenclature. S. Karger, Basel.

    Google Scholar 

  14. Hicks G. and Dewald G. (1985) Incidence and types of variant Ph chromosomes in 378 patients with a Ph chromosome. Karyogram. 11, 105.

    Google Scholar 

  15. Fitzgerald P. and Morris C. (1991) Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangement? Cancer Genet. Cytogenet. 57, 143–151.

    Article  CAS  PubMed  Google Scholar 

  16. Koduru P., Goh J., Allen S., et al. (1991) Different patterns of chromosome and molecular breakage in classic Ph chronic myelogenous leukemia (CML) and variant Ph1 CML. Hematol. Pathol. 5, 57–66.

    CAS  PubMed  Google Scholar 

  17. Hagemeijer A., Bartram C., Smit E., van Agthoven A., and Bootsma D. (1984) Is chromosomal region 9q34 always involved in variants of the Ph translocation? Cancer Genet. Cytogenet. 13, 1–16.

    Article  CAS  PubMed  Google Scholar 

  18. van der Plas D., Grosveld G., and Hagemeijer A. (1991) Review of clinical, cytogenetic and molecular aspects of Ph-negative CML. Cancer Genet. Cytogenet. 52, 143–156.

    Article  PubMed  Google Scholar 

  19. Travis L. B., Pierre R. V., and DeWald G. W. (1986) Ph1-negative chronic granulocytic leukemia: a nonentity. Am. J. Clin. Pathol. 85, 186–193.

    CAS  PubMed  Google Scholar 

  20. Westbrook C., Rubin C., Carrino J., Le Beau M., Bernards A., and Rowley J. (1988) Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis. Blood 71, 697–702.

    CAS  PubMed  Google Scholar 

  21. Heisterkamp N., Stephenson J., Groffen J., Hansen P., de Klein A., Bartram C. and Grosveld G. (1983) Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306, 239–242.

    Article  CAS  PubMed  Google Scholar 

  22. Groffen J., Stephenson J., Heisterkamp N., de Klein A., Bartram C., and Grosveld G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, Bcr, on chromosome 22. Cell 36, 93–99.

    Article  CAS  PubMed  Google Scholar 

  23. Rodenhuis S., Smets L., Slater R., Behrendt H., and Veerman A. (1985) Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia (letter). N. Engl. J. Med. 313, 51–52.

    Article  CAS  PubMed  Google Scholar 

  24. Selleri L., Narni F., Emilia G., Colo A., Zucchini P., and Venturelli D. (1987) Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region. Blood 70, 1659–1664.

    CAS  PubMed  Google Scholar 

  25. Hochhaus A., Reiter A., Skladny H., Melo J., Sick C., and Berger U. (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88, 2236–2240.

    CAS  PubMed  Google Scholar 

  26. Bernards A., Rubin C., Westbrook C., Paskind M., and Baltimore D. (1987) The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol. Cell. Biol. 7, 3231–3236.

    CAS  PubMed  Google Scholar 

  27. Stock W., Westbrook C., Peterson B., et al. (1997) Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B study. J. Clin. Oncol. 15, 26.

    CAS  PubMed  Google Scholar 

  28. Shtivelman B., Lifshitz R., Gale R., and Canaani E. (1983) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550.

    Article  Google Scholar 

  29. Konopka J., Watanabe S., Singer J., Collins S., and Witte O. (1985) Cell lines and clinical isolates derived from Ph-positive chronic myelogenous leukemia patients express C-abl proteins with a common structural alteration. Proc. Natl. Acad. Sci. USA 82, 1810.

    Article  CAS  PubMed  Google Scholar 

  30. Arnoldus E., Wiegant J., Noordermeer I., et al. (1990) Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet. Cell. Genet. 54, 108–111.

    Article  CAS  PubMed  Google Scholar 

  31. Tkachuk D., Westbrook C., Andreeff M., et al. (1990) Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 250, 559–562.

    Article  CAS  PubMed  Google Scholar 

  32. Sinclair P., Green A., Grace C., and Nacheva E. (1997) Improved sensitivity of BCRABL detection: A triple-probe three-color fluorescence in situ hybridization system. Blood 90, 1395–1402.

    CAS  PubMed  Google Scholar 

  33. Seong D., Kantarjian H., Ro J., et al. (1995) Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86, 2343–2349.

    CAS  PubMed  Google Scholar 

  34. Seong C.-M., Giralt S., Kantarjian H., et al. (2000) Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J. Clin. Oncol. 18, 1831–1836.

    CAS  PubMed  Google Scholar 

  35. Appelbaum F., Clift R., Radich J., Anasetti C., and Buckner C. (1995) Bone marrow transplantation for chronic myelogenous leukemia. Semin. Oncol. 22, 405–411.

    CAS  PubMed  Google Scholar 

  36. ICSG. (1994) Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820–825.

    Article  Google Scholar 

  37. Talpaz M., Kantarjian H., Kurzrock R., Trujillo J., and Gutterman J. (1991) Interferonalpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann. Int. Med. 114, 532–538.

    CAS  PubMed  Google Scholar 

  38. Kloke O., Niederle N., Qiu J., et al. (1993) Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br. J. Haematol. 83, 399–403.

    Article  CAS  PubMed  Google Scholar 

  39. Allan N., Richards S., and Shepherd P. (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345, 1392–1397.

    Article  CAS  PubMed  Google Scholar 

  40. Silver R. T., Woolf S. H., Hehlmann R., et al. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94, 1517–1536.

    CAS  PubMed  Google Scholar 

  41. Thiesing J., Ohno-Jones S., Kolibaba K., and Druker B. (2000) Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 96, 3195–3199.

    CAS  PubMed  Google Scholar 

  42. Druker B. (1999) Status of BCR-ABL Tyrosine Kinase Inhibitors in CML, in Hematology (Schechter G., ed.), American Society of Hematology, Washington D. C., pp. 160–171.

    Google Scholar 

  43. Laurent E., Talpaz M., Kantarjian H., and Kurzrock R. (2001) The BCR gene and Philadelphia chromosome-positibe leukemogenesis. Cancer Res. 61, 2343–2355.

    CAS  PubMed  Google Scholar 

  44. Kobzev Y., Domracheva E., Zakharova A., Khoroshko N., Turkina A., and Dewald G. (1998) Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia. Cancer Genet. Cytogenet. 106, 128–134.

    Article  CAS  PubMed  Google Scholar 

  45. Nacheva E., Holloway T., Brown K., Bloxham D., and Green A. (1993) Philadelphianegative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br. J. Haematol. 87, 409–412.

    Article  Google Scholar 

  46. Dewald G., Ketterling R., Wyatt W., and Stupca P. (2002) Cytogenetic studies in neoplastic hematologic disorders, in Clinical Laboratory Medicine (McClatchey K., ed.), Williams and Wilkens, Baltimore, pp. 658–685.

    Google Scholar 

  47. Dewald G., Stallard R., Alsaadi A., et al. (2000) A multi-center investigation with D-FISH BCR/ABL1 probes. Cancer Genet. Cytogenet. 116, 97–104.

    Article  CAS  PubMed  Google Scholar 

  48. Dewald G., Wyatt W., and Silver R. (1999) Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 34, 481–491.

    CAS  PubMed  Google Scholar 

  49. Sinclair P. B., Nacheva E. P., Leversha M., et al. (2000) Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95, 738–743.

    CAS  PubMed  Google Scholar 

  50. Le Gouill S., Talmant P., Milpied N., et al. (2000) Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J. Clin. Oncol. 18, 1533–1538.

    PubMed  Google Scholar 

  51. Sandberg A. (1990) Chronic myelocytic leukemia, in The Chromosomes in Human Cancer and Leukemia (Sandberg A. ed.), Elsevier, New York, pp. 458–520.

    Google Scholar 

  52. Thaler J., Gastl G., Fluckinger T., et al. (1996) Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. Ann. Hematol. 72, 349–355.

    Article  CAS  PubMed  Google Scholar 

  53. Kantarjian H., Smith T., O’Brien S., Beran M., Pierce S., and Talpaz M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferonalpha therapy. Ann. Intern. Med. 122, 254.

    CAS  PubMed  Google Scholar 

  54. Hehlmann R., Heimpel H., Hasford J., et al. (1994) Randomized comparison of interferonalpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84, 4064–4077.

    CAS  PubMed  Google Scholar 

  55. ICSG. (1995) Italian Cooperative Study Group on Chronic Myeloid Leukemia. Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. Leukemia 9, 1648–1652.

    Google Scholar 

  56. Cuneo A., Bigoni R., Emmanuel B., et al. (1998) Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 12, 1718–1723.

    Article  CAS  PubMed  Google Scholar 

  57. Nolte M., Werner M., Ewig M., et al. (1996) Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. Leuk. Lymphoma. 22, 287–294.

    Article  CAS  PubMed  Google Scholar 

  58. Muhlmann J., Thaler J., Hilbe W., et al. (1998) Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 21, 90–100.

    Article  CAS  PubMed  Google Scholar 

  59. Lesser M. L., Dewald G. W., Sison C. P., and Silver R. T. (2000) Correlation of three methods of measuring cytogenetic response in chronic myeloid leukemia (CML). Canc. Genet. Cytogenet. In press.

    Google Scholar 

  60. Mitelman F. (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk. Lymphoma 11 Suppl, 11–15.

    Article  PubMed  Google Scholar 

  61. Diez-Martin J. L., Dewald G. W. and Pierre R. V. (1988) Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia. Am. J. Hematol. 27, 194–203.

    Article  CAS  PubMed  Google Scholar 

  62. Sadamori N., Gomez G., and Sandberg A. (1983) Therapeutic and prognostic value of initial chromosomal findings at the blastic phase of Ph1-positive chronic myeloid leukemia. Blood 61, 935–939.

    CAS  PubMed  Google Scholar 

  63. Dewald G. and Wright P. (1995) Chromosome abnormalities in the myeloproliferative disorders. Semin. Oncol. 22, 341–354.

    CAS  PubMed  Google Scholar 

  64. Dewald G. W., Juneau A. L., Schad C. R., and Tefferi A. (1997) Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia. Cancer Genet. Cytogenet. 94, 59–66.

    Article  CAS  PubMed  Google Scholar 

  65. Liu Yin J. and Tobal K. (1999) Detection of minimal residual disease in acute myeloid leukaemia: Methodologies, clinical and biological significance. Brit. J. Haematol. 106, 578–590.

    Article  Google Scholar 

  66. Hochhaus A., Lin F., Reiter A., et al. (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87, 1549–1555.

    CAS  PubMed  Google Scholar 

  67. Hochhaus A., Lin F., Reiter A., et al. (1996) Quantitative molecular methods to monitor the response of CML patients to interferon-α. Bone Marrow Transplant. 17, S41.

    PubMed  Google Scholar 

  68. Chase A., Grand F., Zhang J. G., Blackett N., Goldman J., and Gordon M. (1997) Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 18, 246–253.

    Article  CAS  PubMed  Google Scholar 

  69. Thall P., Jacoby D., and Zimmerman S. (1996) Estimating genomic category probabilities from fluorescent in situ hybridization counts with misclassification. Appl. Statist. 45, 431–446.

    Article  Google Scholar 

  70. Dewald G., Stallard R., Al Saadi A., et al. (1998) A multicenter investigation with interphase fluorescence in situ hybridization using X-and Y-chromosome probes. Am. J. Med. Genet. 76, 318–326.

    Article  CAS  PubMed  Google Scholar 

  71. Westgard J., Quam E., and Barry P. (eds.) (1998) How do you plot and interpret results on a Levey-Jennings chart? Westgard Quality Corp., Madison, WI.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory Medicine and Medical Genetics, Mayo Clinic, Rochester, MN

    Gordon W. Dewald

Authors
  1. Gordon W. Dewald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. London Health Sciences Center, London

    Yao-Shan Fan

  2. The University of Western Ontario, Ontario, Canada

    Yao-Shan Fan

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Humana Press Inc.

About this protocol

Cite this protocol

Dewald, G.W. (2002). Interphase FISH Studies of Chronic Myeloid Leukemia. In: Fan, YS. (eds) Molecular Cytogenetics. Methods in Molecular Biology™, vol 204. Humana Press. https://doi.org/10.1385/1-59259-300-3:311

Download citation

  • DOI: https://doi.org/10.1385/1-59259-300-3:311

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-006-9

  • Online ISBN: 978-1-59259-300-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation